Laura Miller

Dr. Laura Miller

United States Department of Agriculture, Agricultural Research Service
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Virus Research
Verified
Journal Article
Closed access
SBSusan L. Brockmeier
Susan L. Brockmeier
CLCrystal L. Loving
Crystal L. Loving
AVAnn C. Vorwald
Ann C. Vorwald
MKMarcus E. Kehrli
Marcus E. Kehrli
RBRodney B. Baker
Rodney B. Baker
KFKay S. Faaberg
Kay S. Faaberg

1 January 2013 in Virology
Verified
Journal Article
Closed access
BGBaoqing Guo
Baoqing Guo
KLKelly M. Lager
Kelly M. Lager
JHJamie N. Henningson
Jamie N. Henningson
LMLaura Miller
Laura Miller
SSSarah N. Schlink
Sarah N. Schlink
KFKay Faaberg
Kay Faaberg

27 August 2004 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
LMLaura Miller
Laura Miller
WLW. W. Laegreid
W. W. Laegreid
JBJ. L. Bono
J. L. Bono
CCC. G. Chitko-McKown
C. G. Chitko-McKown
JFJ. M. Fox
J. M. Fox

1 December 2016 in Virus Research
Verified
Journal Article
Closed access
KCKimberly Crawford
Kimberly Crawford
KLKelly M. Lager
Kelly M. Lager
VKVikas Kulshreshtha
Vikas Kulshreshtha
LMLaura Miller
Laura Miller
KFKay Faaberg
Kay Faaberg

1 June 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
JLJiuyi Li
Jiuyi Li
LMLaura Miller
Laura Miller
Yongming SangYongming Sang
Yongming Sang
Porcine reproductive and respiratory syndrome (PRRS) remains a formidable challenge for the global pig industry. Caused by PRRS virus (PRRSV), this disease primarily affects porcine reproductive and respiratory systems, undermining effective host interferon and other immune responses, resulting in vaccine ineffectiveness. In the absence of specific antiviral treatments for PRRSV, vaccines play a crucial role in managing the disease. The current market features a range of vaccine technologies, including live, inactivated, subunit, DNA, and vector vaccines, but only modified live virus (MLV) and killed virus (KV) vaccines are commercially available for PRRS control. Live vaccines are promoted for their enhanced protective effectiveness, although their ability to provide cross-protection is modest. On the other hand, inactivated vaccines are emphasized for their safety profile but are limited in their protective efficacy. This review updates the current knowledge on PRRS vaccines’ interactions with the host interferon system, and other immunological aspects, to assess their current status and evaluate advents in PRRSV vaccine development. It presents the strengths and weaknesses of both live attenuated and inactivated vaccines in the prevention and management of PRRS, aiming to inspire the development of innovative strategies and technologies for the next generation of PRRS vaccines.

1 December 2004 in Veterinary Immunology and Immunopathology
Verified
Journal Article
Closed access
LMLaura Miller
Laura Miller
JFJames M. Fox
James M. Fox